ReviewJournal of clinical medicine2026
Lifetime Management of Transcatheter Aortic Valve Replacement: A Guide to Decision-Making and Future Reinterventions.
Review in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Transcatheter aortic valve implantation: contemporary management from first valve choice to reintervention.Internal medicine journal · 2026Review
- Early outcomes and resource utilization across contemporary transcatheter and surgical valve interventions: a single-center observational study.BMC research notes · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of severe aortic stenosis, evolving from a therapy reserved for inoperable patients to a first-line option across all surgical risk categories. As TAVR expands to younger patients with longer life expectancies, lifetime management strategies become paramount. This comprehensive review examines the important role of computed tomography (CT) planning in optimizing initial valve selection and predicting future reintervention feasibility. We discuss the decision framework between TAVR and surgical aortic valve replacement (SAVR) as initial therapy, strategies to optimize the index TAVR procedure, including minimizing patient-prosthesis mismatch, reducing paravalvular regurgitation, preventing conduction abnormalities and coronary obstruction, and facilitating future reinterventions. For patients requiring redo procedures, we analyse TAVR-in-TAVR considerations, including risk plane assessment, coronary access preservation, and leaflet modification techniques. Future directions include advances in valve design, artificial intelligence integration in procedural planning, and development of personalized risk assessment tools. Successful lifetime management requires multidisciplinary collaboration and individualized treatment planning to optimize outcomes throughout a patient's lifetime journey with aortic valve disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.